- Home
- TOPS vs LSTA Comparison
TOPS vs LSTA Comparison
Compare TOPS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- LSTA
- Stock Information
- Founded
- TOPS 2000
- LSTA 1980
- Country
- TOPS Greece
- LSTA United States
- Employees
- TOPS N/A
- LSTA N/A
- Industry
- TOPS Marine Transportation
- LSTA Misc Health and Biotechnology Services
- Sector
- TOPS Consumer Discretionary
- LSTA Health Care
- Exchange
- TOPS Nasdaq
- LSTA Nasdaq
- Market Cap
- TOPS 25.1M
- LSTA 22.3M
- IPO Year
- TOPS 2004
- LSTA N/A
- Fundamental
- Price
- TOPS $5.41
- LSTA $2.32
- Analyst Decision
- TOPS
- LSTA Strong Buy
- Analyst Count
- TOPS 0
- LSTA 2
- Target Price
- TOPS N/A
- LSTA $23.50
- AVG Volume (30 Days)
- TOPS 5.6K
- LSTA 21.5K
- Earning Date
- TOPS 11-13-2025
- LSTA 11-11-2025
- Dividend Yield
- TOPS N/A
- LSTA N/A
- EPS Growth
- TOPS N/A
- LSTA N/A
- EPS
- TOPS 1.09
- LSTA N/A
- Revenue
- TOPS $86,127,000.00
- LSTA $1,070,000.00
- Revenue This Year
- TOPS $9.90
- LSTA N/A
- Revenue Next Year
- TOPS N/A
- LSTA N/A
- P/E Ratio
- TOPS $5.00
- LSTA N/A
- Revenue Growth
- TOPS 3.83
- LSTA N/A
- 52 Week Low
- TOPS $5.00
- LSTA $1.87
- 52 Week High
- TOPS $11.47
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- TOPS 43.27
- LSTA 48.62
- Support Level
- TOPS $5.30
- LSTA $2.10
- Resistance Level
- TOPS $5.69
- LSTA $2.43
- Average True Range (ATR)
- TOPS 0.19
- LSTA 0.16
- MACD
- TOPS 0.01
- LSTA 0.02
- Stochastic Oscillator
- TOPS 27.50
- LSTA 65.38
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.